In this part 2, Kirsten Axelsen, MS, discusses racial disparities, AI in prior authorization, and payers’ readiness for the next wave of CLL therapies.
Publication|Articles|June 18, 2025
- June 2025
- Volume 31
- Issue Spec. No. 7
- Pages: SP402-SP404
Will Subcutaneous PD-1/PD-L1 Inhibitors Be a Game Changer?
Author(s)Mary Caffrey
Advertisement
Advertisement
By this fall, the FDA may approve a subcutaneous (SC) injection of the world’s top-selling cancer drug, pembrolizumab (Keytruda; Merck), that can be delivered to patients in 5 minutes or less. It is a change that Merck’s Marjorie Green, MD, senior vice president and head of oncology clinical development, predicts will “build on this breakthrough medicine to give patients and those who treat them better experiences.”1
Related to this article
Kirsten Axelsen, MS, discusses gaps in biomarker testing, nonmedical barriers, and utilization management from a new report on access to CLL care.
Earlier Alzheimer disease detection is outpacing specialist capacity and may widen gaps for underserved patients, Cleveland experts say.
Six studies found liver transplant disparities by insurance, region, ethnicity, and sex, plus links between unmet social needs and frailty in cirrhosis.
A new meta-analysis finds pulmonary rehabilitation and other nonpharmacological interventions ease lung cancer cough, dyspnea, and improve QOL.
Machine learning models for upper extremity soft tissue sarcoma had a C-index of 0.79 for local recurrence, similar to nomograms, in a 188-patient cohort.
Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.
SGLT2 inhibitors were linked to hemoglobin gains of about 1.0 to 1.6 g/dL in small MDS and MPN studies, but a review found no randomized trials to confirm.
Advertisement
Advertisement